Literature DB >> 24610618

Expression of cyclinD1 and Ki-67 proteins in gliomas and its clinical significance.

D-W Qu1, H-S Xu, X-J Han, Y-L Wang, C-J Ouyang.   

Abstract

OBJECTIVES: To investigate the expression of cyclinD1 and Ki-67 proteins in gliomas and its significance. PATIENTS AND METHODS: The immunohistochemistry was used to detect the expression of cyclinD1 and Ki-67 proteins in 18 cases of normal brain tissues, 32 cases of low-grade gliomas, and 24 cases of high-grade gliomas.
RESULTS: The cyclinD1 positive ratio in normal brain tissues, low-grade gliomas, and high-grade gliomas were 4/18, 15/32, and 18/24, respectively, with statistically significant difference (p < 0.05). Differences were significant by pairwise comparison between normal brain tissue with high-grade gliomas and low-grade gliomas with high-grade glioma groups (p < 0.01). However, there was no significant differences between normal brain tissue with low-grade gliomas. The Ki-67 positive ratio in normal brain tissues, low-grade gliomas, and high-grade gliomas were 5/18, 21/32, and 20/24, respectively. The difference among three tissues was statistically significant (p < 0.05). Differences were significant by pairwise comparison between normal brain tissue with low-grade gliomas and normal brain tissue with high-grade glioma group (p < 0.01). There is no difference between low-grade gliomas and high-grade gliomas (p > 0.05). Spearman's rank correlation confirmed that cyclinD1 and Ki-67 was positively correlated in low-grade gliomas and high-level brain tumor (p < 0.05), but no correlation in the normal brain tissue (p > 0.05).
CONCLUSIONS: The expression of CyclinD1 and Ki-67 increased in gliomas, suggesting that both may play an important role in the occurrence of gliomas.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24610618

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  CT perfusion with acetazolamide challenge in C6 gliomas and angiogenesis.

Authors:  Na Lu; Yue Di; Xiao-Yuan Feng; Jin-Wei Qiang; Jia-wen Zhang; Yong-gang Wang; Ying Liu
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

2.  Insights into the clinical value of cyclin-dependent kinase 5 in glioma: a retrospective study.

Authors:  Ruan Yushan; Chen Wenjie; Huang Suning; Dang Yiwu; Zhong Tengfei; Wickramaarachchi Mihiranganee Madushi; Luo Feifei; Zhang Changwen; Wen Xin; Gopaul Roodrajeetsing; Li Zuyun; Chen Gang
Journal:  World J Surg Oncol       Date:  2015-07-25       Impact factor: 2.754

3.  Radiomic prediction models for the level of Ki-67 and p53 in glioma.

Authors:  Xiaojun Sun; Peipei Pang; Lin Lou; Qi Feng; Zhongxiang Ding; Jian Zhou
Journal:  J Int Med Res       Date:  2020-05       Impact factor: 1.671

4.  Significance of cyclin D1 overexpression in progression and radio-resistance of pediatric ependymomas.

Authors:  Muh-Lii Liang; Tsung-Han Hsieh; Yun-Ru Liu; Yi-Wei Chen; Yi-Yen Lee; Feng-Chi Chang; Shih-Chieh Lin; Ming-Chao Huang; Ho Donald Ming-Tak; Tai-Tong Wong; Yun Yen; Muh-Hwa Yang
Journal:  Oncotarget       Date:  2017-12-20

5.  An Immunohistochemical Study of Cyclin D1 Expression in Astrocytic Tumors and its Correlation with Tumor Grade.

Authors:  Parvin Mahzouni; Fatemeh Taheri
Journal:  Iran J Pathol       Date:  2019-08-01

6.  Expression of TCF7L2 in Glioma and Its Relationship With Clinicopathological Characteristics and Patient Overall Survival.

Authors:  Shiyuan Jing; Lei Chen; Song Han; Ning Liu; MingYang Han; Yakun Yang; Changxiang Yan
Journal:  Front Neurol       Date:  2021-07-08       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.